29.09.2023 SYNLAB AG  DE000A2TSL71

EQS-Adhoc: SYNLAB AG: Cinven announces public acquisition offer | Conclusion of Investment Agreement


 

EQS-Ad-hoc: SYNLAB AG / Key word(s): Agreement/Strategic Company Decision
SYNLAB AG: Cinven announces public acquisition offer | Conclusion of Investment Agreement

29-Sep-2023 / 08:17 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed an investment agreement (“Investment Agreement”) with Ephios Luxembourg S.à r.l. and its subsidiary Ephios Bidco GmbH, two holding companies controlled by investment funds advised by Cinven Limited.
Concurrently, Ephios Luxembourg S.à r.l. announced its decision to make a voluntary public acquisition offer to the shareholders of SYNLAB to acquire all shares outstanding of SYNLAB (“Offer”) not directly held by it at a price of €10.00 per SYNLAB share. Ephios Luxembourg S.à r.l. already holds approx. 43.24% of the voting rights in SYNLAB. The Offer will not be subject to a minimum acceptance threshold.
As a basis for the Offer, the Investment Agreement was concluded to specify the offer process and provide for the future cooperation. This includes, among other things, agreements regarding the support of the corporate and growth strategies of the Company as well as the interests of employees of SYNLAB Group.


End of Inside Information

29-Sep-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: [email protected]
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1737521

 
End of Announcement EQS News Service

1737521  29-Sep-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1737521&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 0,00 1.807,90 1.906,10 2.621,20 3.764,92 3.250,52 2.635,16
EBITDA1,2 0,00 382,90 397,40 679,20 1.179,89 532,98 353,28
EBITDA-Marge3 0,00 21,18 20,85 25,91 31,34 16,40
EBIT1,4 0,00 138,80 71,90 315,50 914,53 231,68 59,16
EBIT-Marge5 0,00 7,68 3,77 12,04 24,29 7,13 2,25
Jahresüberschuss1 0,00 -42,10 -108,00 259,10 627,54 152,52 92,96
Netto-Marge6 0,00 -2,33 -5,67 9,88 16,67 4,69 3,53
Cashflow1,7 0,00 120,30 238,60 904,70 1.011,70 629,63 363,13
Ergebnis je Aktie8 0,00 -0,19 -0,49 1,16 2,82 0,68 0,42
Dividende8 0,00 0,00 0,00 0,00 0,33 0,33 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Synlab
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2TSL7 10,440 2.320,00
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
16,06 20,96 0,77 15,44
KBV KCV KUV EV/EBITDA
0,99 6,39 0,88 8,56
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,33 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 08.08.2024 07.11.2024 25.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,74% -0,82% -8,58% 8,19%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SYNLAB AG  ISIN: DE000A2TSL71 können Sie bei EQS abrufen


Medtech , A2TSL7 , SYAB , XETR:SYAB